Why did Cytek Biosciences (CTKB) stock move recently?

On 9/1/2026, Cytek Biosciences moved -3.3% — No specific company catalyst identified for the decline; recent coverage highlights a new BlackRock institutional stake disclosed today, with no negative developments reported. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Cytek Biosciences (CTKB) overvalued or fairly valued?

MarketChacha shows Cytek Biosciences's valuation in context — a forward P/E of about 66.6, a price-to-book of about 1.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Cytek Biosciences's revenue?

Cytek Biosciences reported revenue of $201.5M for FY2025, with net profit of $-66.5M, per official filings.

What is the share price of Cytek Biosciences (CTKB)?

Cytek Biosciences last traded at $4.70 (+0.0% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Cytek Biosciences

CTKB · NYSE · Healthcare · United States

Snapshot

TickerCTKB

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees682

HeadquartersFremont, United States

Websitecytekbio.com

Filings tracked15

About Cytek Biosciences

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Who owns it

Insiders8.5%
Institutions63.1%
Public & other28.4%

214 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.7.37%
Millennium Management Llc7.18%
Boston Partners5.89%
HHLR Advisors, LTD5.12%
Topline Capital Management, LLC4.83%
Vanguard Capital Management LLC3.80%
Geode Capital Management, LLC2.35%
Dimensional Fund Advisors LP2.01%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 26.7 points over the period — profitability is trending down.

Net margin trend-6.3% → -33.0%

Margin has compressed by about 26.7 points over the period — profitability is trending down.

Return on equity-19.5%

Latest ROE of -19.5% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $63.6M · EPS 0.03

Est. earnings growth +110.4%

Next fiscal year

Rev $223.2M · EPS 0.07

Est. earnings growth +158.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$201.5M

Net margin

-33.0%

ROE

-19.5%

Revenue CAGR (2y)

+2.2%

Net profit (FY2025)

$-66.5M

Ask MarketChacha about CTKB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Sep 1, 2026
No specific company catalyst identified for the decline; recent coverage highlights a new BlackRock institutional stake disclosed today, with no negative developments reported.
source 1 ↗source 2 ↗· confidence: low
Aug 25, 2026
No specific company catalyst identified for the move; CTKB rose with broader market/sector trends following recent Q2 results and a mixed but mostly favorable Aug 21 patent verdict.
source 1 ↗source 2 ↗· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$201.5M	$-66.5M	—	-33.0%	-19.5%
FY2024	$200.5M	$-6.0M	—	-3.0%	-1.5%
FY2023	$193.0M	$-12.1M	-0.09	-6.3%	-3.1%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q2	$48.1M	$-12.2M	-25.3%
2026Q1	$44.1M	$-18.9M	-42.7%
2025Q3	$52.3M	$-5.5M	-10.5%
2025Q2	$45.6M	$-5.6M	-12.2%
2025Q1	$41.5M	$-11.4M	-27.5%
2024Q3	$51.5M	$941,000	1.8%
2024Q2	$46.6M	$-10.4M	-22.4%
2024Q1	$44.9M	$-6.2M	-13.8%
2023Q3	$48.0M	$-6.5M	-13.5%
2023Q2	$49.7M	$-4.4M	-8.8%
2023Q1	$37.1M	$-6.8M	-18.4%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/5/2026material
10-Q filing
SEC8/5/2026
8-K — Executive/director change
SEC7/15/2026material
8-K — Executive/director change
SEC6/25/2026material
8-K — Shareholder vote results
SEC6/16/2026material
8-K — Executive/director change
SEC6/2/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Results of operations, Exhibits
SEC2/26/2026material
10-K filing
SEC2/26/2026
8-K — Results of operations, Exhibits
SEC1/13/2026material

2025

8-K — Results of operations, Exhibits
SEC11/5/2025material
10-Q filing
SEC11/5/2025
8-K — Results of operations, Exhibits
SEC8/6/2025material
10-Q filing
SEC8/6/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.